Source-grounded facts extracted from WINDTREE THERAPEUTICS INC /DE/'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
John Tattory was appointed as Interim Chief Financial Officer at WINDTREE THERAPEUTICS INC /DE/.
“On January 18, 2023, the board of directors of the Company appointed John Tattory as Interim Chief Financial Officer, effective as of the Effective Date.”
John P. Hamill resigned as Senior Vice President, Chief Financial Officer and Corporate Secretary at WINDTREE THERAPEUTICS INC /DE/.
“On January 17, 2023, John P. Hamill, the Senior Vice President, Chief Financial Officer and Corporate Secretary of Windtree Therapeutics, Inc. (the “Company”) notified the Company of his decision to resign effective as of January 27, 2023 (the “Effective Date”).”
WINDTREE THERAPEUTICS INC /DE/: Created Series A Preferred Stock with specified voting, liquidation, and redemption rights via a certificate of designation (effective 2022-11-17).
“Series A Preferred Stock On November 17, 2022, the board of directors (the “ Board ”) of Windtree Therapeutics, Inc. (the “ Company ”), declared a dividend of one one-thousandth (1/1,000 th ) of a share of Series A Preferred Stock, par value $0.001 per share (“ Series A Preferred Stock ”), for each outstanding share of the Company’s common stock, par value $0.001 per share (“ Common Stock ”) to stockholders of record at 5:00 p.m. Eastern Time on November 28, 2022 (the “ Record Date ”).”
WINDTREE THERAPEUTICS INC /DE/ reported third quarter ended September 30, 2022 results: net income $4.1 million, EPS ($0.13 per basic share).
“The Company reported a net loss of $4.1 million ( $0.13 per basic share) on 31.1 million weighted-average common shares outstanding for the quarter ended September 30, 2022 , compared to a net loss of $8.2 million ( $0.31 per basic share) on 26.7 million weighted average common shares outstanding for the comparable period in 2021.”
Evan Loh resigned as Director at WINDTREE THERAPEUTICS INC /DE/.
“On May 9, 2022, Evan Loh, M.D., a member of the Board of the Company, notified the Board that due to other professional commitments, he will not stand for re-election to the Board at the Company’s 2022 Annual Meeting of Stockholders (the “Annual Meeting”) and, as a result, his term will end upon the conclusion of the Annual Meeting on June 7, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.